Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
AlzeCure Pharma
AlzeCure Pharma
Activities:
Drug Delivery
Research & Development
X
LinkedIn
Trending Articles
Sanofi opens €558m modular vaccine and biologics manufacturing facility in Singapore
The biopharmaceutical manufacturing facility will allow Sanofi to manufacture up to four vaccines and biologic medicines simultaneously, while also enhancing the area's...
Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D
Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
Ingenza and HydRegen collaborate to optimise biomanufacturing sustainability
The companies will work together to optimise and scale HydRegen's range of amine-based biocatalysts, which are more sustainable and cost-effective than traditional metal catalysts
You need to be a subscriber to read this article.
Click here
to find out more.
The new fight against diabetes and obesity
Incretin mimetics administered by autoinjectors or pens enable significant weight reduction and offer an important way to combat obesity and prevent type 2 diabetes. As such,...
IMed Consultancy helps Toby Orthopaedics navigate UK regulations
Regulatory consultancy ensures compliance and confidence for Miami-based company
Upcoming event
CPhI Middle East
10–12 December 2024 | Conference | Riyadh, Saudi Arabia
See all
Related Content
Training & Education
AlzeCure releases paper on Trk receptor modulation for Alzheimer's disease
The paper details the potential of Trk receptor modulation in treating neurological conditions such as Alzheimer's and Parkinson's disease
Research & Development
AlzeCure elect Dr Jan Lundberg as a new board member
Dr Lundberg has experience in leadership position in global pharmaceutical companies, including AstraZeneca and Eli Lilly
AlzeCure's Alzheimer's project NeuroRestore ACD856 granted an additional patent
ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF and NGF
Manufacturing
AlzeCure Pharma receives patent for anti-Alzheimer's drug
ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain
Subscribe now